CD109

Across TCGA pan-cancer cohorts, CD109 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CD109 data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CD109 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD109 expression acts as an unfavorable survival marker.

PDAC, LSCC, and UCEC are the cancer types where CD109 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	0.228	0.784	<.001	40	view →
LSCC	OS	Quartile	All	0.826	0.998	.014	10	view →
UCEC	DFS	Quartile	III,IV	0.248	1.000	.040	8	view →
HNSC	DFS	Tertile	IV	0.883	1.000	.026	5	view →
LUAD	OS	Quartile	II,III,IV	0.285	0.709	.049	2	view →
CCRCC	OS	Median	II,III,IV	0.713	0.912	.020	1	view →
GBM	OS	Median	All	0.777	0.934	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CD109–PDAC (DFS)

Open the PDAC breakdown →